Attached files
| file | filename |
|---|---|
| EX-4.2 - EX-4.2 - OPIANT PHARMACEUTICALS, INC. | exhibit42.htm |
| EX-32.2 - EX-32.2 - OPIANT PHARMACEUTICALS, INC. | opnt12312020exhibit322.htm |
| EX-32.1 - EX-32.1 - OPIANT PHARMACEUTICALS, INC. | opnt12312020exhibit321.htm |
| EX-31.2 - EX-31.2 - OPIANT PHARMACEUTICALS, INC. | opnt12312020exhibit312.htm |
| EX-31.1 - EX-31.1 - OPIANT PHARMACEUTICALS, INC. | opnt12312020exhibit311.htm |
| 10-K - 10-K - OPIANT PHARMACEUTICALS, INC. | opnt-20201231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Form S-3 (File No. 333-252012) and Form- S-8 (File Nos. 333-221759, 333-224239, 333-230450, and 333-237050) of our report dated March 4, 2021 with respect to the consolidated financial statements of Opiant Pharmaceuticals, Inc. included in the Annual Report on Form 10 K for the year ended December 31, 2020.
/s/ MaloneBailey, LLP www.malonebailey.com
Houston, Texas
March 4, 2021